New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 1000 [iu] - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 2000 [iu] (recombinant factor viii) - injection with diluent - 2000 iu - active: octocog alfa 2000 [iu] (recombinant factor viii) excipient: calcium chloride glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 250 [iu] - injection with diluent - 250 iu - active: octocog alfa 250 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 500 [iu] - injection with diluent - 500 iu - active: octocog alfa 500 [iu] excipient: calcium chloride dihydrate glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

bayer new zealand limited - octocog alfa 3000 [iu] (recombinant factor viii) - injection with diluent - 3000 iu - active: octocog alfa 3000 [iu] (recombinant factor viii) excipient: calcium chloride glycine histidine polysorbate 80 sodium chloride sucrose water for injection water for injection - kogenate fs is indicated in congenital factor viii deficiency (haemophilia a) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency).advate does not contain von willebrand factor in pharmacologically effective quantities and is therefore not indicated in von willebrand disease.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency).this preparation does not contain von willebrand factor and is therefore not indicated in von willebrand's disease.

Liên Minh Châu Âu - Tiếng Anh - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1000 [iu];   - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1500 [iu];   - injection with diluent - 1500 iu - active: octocog alfa 1500 [iu]   excipient: calcium chloride dihydrate glutathione histidine mannitol polysorbate 80 sodium chloride trehalose dihydrate trometamol water for injection - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.